L26/P-806 Ovarian Reserve and IVF Outcomes in Patients with Sickle Cell Anemia: A Systematic Review
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1133 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Habte und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Are anti-Mullerian hormone (AMH) levels and IVF outcomes altered in individuals with sickle cell anemia (SCA), and is hydroxyurea exposure associated with diminished ovarian reserve? Summary answer AMH declines with age and earlier in individuals with SCA compared with controls, while the association between hydroxyurea use and diminished ovarian reserve is inconsistent. What is known already SCA is the most common hemoglobinopathy and is characterized by chronic anemia and progressive end-organ damage. Hydroxyurea is a cornerstone of therapy to reduce vaso-occlusive complications and their associated morbidity and mortality. AMH levels are markers of ovarian reserve, which predict the number of oocytes retrieved during IVF. To date, no comprehensive synthesis has evaluated ovarian reserve and assisted reproductive outcomes in this population using contemporary risk of bias and certainty of evidence. Study design, size, duration The systematic review followed MOOSE guidelines. PubMed, MEDLINE, EMBASE, CINAHL, Evidence Based Medical Reviews, Scopus, and Cochrane Central were searched from inception to December 31, 2024, for peer-reviewed studies. Two reviewers independently screened studies and extracted data. Risk of bias was assessed using ROBINS-I and evidence quality using GRADE. Primary outcomes included AFC, AMH, and IVF outcomes. Post-transplant studies were excluded. Due to heterogeneity, results were presented descriptively. Participants/materials, setting, methods The search identified 3,791 titles and abstracts, of which 138 articles underwent full-text review and 56 were included for data extraction. Sixteen observational studies reported hormone levels, and two surveys described fertility outcomes. No randomized controlled trials were identified. Twenty studies assessed ovarian reserve using AMH and or AFC, including 19 studies reporting AMH in 684 patients. Five studies evaluated IVF outcomes, and 24 studies included data on hydroxyurea exposure. Main results and the role of chance Most publications reported AMH and/or antral follicle count, either as continuous measures or categorized as low versus normal. Across 56 studies, reporting was inconsistent for key confounders (hormonal contraception, timing/assay of AMH, genotype, disease severity proxies, transfusion burden and iron overload). Heterogeneity precluded pooling. Overall, AMH declines with age and appeared to decrease earlier in individuals with SCA compared with controls, while the association between hydroxyurea use and diminished ovarian reserve is inconsistent. For IVF outcomes, two studies reported lower oocyte yield in younger individuals with SCA (with preserved oocyte maturity rates) and high cycle cancellation. In contrast, other studies found oocyte cryopreservation to be feasible and comparable to peers, while emphasizing the need for special considerations such as pain management and thrombosis risk. Associations between hydroxyurea and ovarian reserve were inconsistent and difficult to interpret due to confounding by indication and poor exposure characterization (start age, duration, dose, and cessation timing). Limitations, reasons for caution This meta-analysis is limited by heterogeneity, small sample sizes, and inconsistent reporting of key confounders, leading to unclear ROBINS-I ratings in several domains. Hydroxyurea exposure was often poorly reported, and data were insufficiently comparable to allow pooling. Wider implications of the findings These findings highlight the need for high-quality prospective studies to clarify if there are independent effects of hydroxyurea on female fertility and to inform evidence-based reproductive counseling and care. Trial registration number No
Zitieren
APA
Habte, R., Anpalagan, T., Sallie, L., Jones, C., Matusiak, K., Malinowski, A., Vlachodimitropoulou, E., & Shehata, N. (2026). L26/P-806 Ovarian Reserve and IVF Outcomes in Patients with Sickle Cell Anemia: A Systematic Review. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1133
Vancouver
Habte R, Anpalagan T, Sallie L, Jones C, Matusiak K, Malinowski A, et al. L26/P-806 Ovarian Reserve and IVF Outcomes in Patients with Sickle Cell Anemia: A Systematic Review. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1133
BibTeX
@article{Habte2026,
author = {Habte, R. and Anpalagan, T. and Sallie, L. and Jones, C. and Matusiak, K. and Malinowski, A.K. and Vlachodimitropoulou, E. and Shehata, N.},
title = {L26/P-806 Ovarian Reserve and IVF Outcomes in Patients with Sickle Cell Anemia: A Systematic Review},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1133}
}
EUVIMED